05th May, 2026 In a decisive move reinforcing India’s drug regulatory framework, the Delhi High Court has delivered a significant judgment that could reshape how pharmaceutical companies approach approvals—especially for Fixed Dose Combinations (FDCs) and other “new drugs.” The ruling…